Voltaren XR, Cataflam (diclofenac) dosing, indications, interactions, adverse effects, and more (2022)

  • acebutolol

    acebutolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of acebutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • aceclofenac

    aceclofenac and diclofenac both increase anticoagulation. Use Caution/Monitor.aceclofenac and diclofenac both increase serum potassium. Use Caution/Monitor.

  • acemetacin

    acemetacin and diclofenac both increase anticoagulation. Use Caution/Monitor.acemetacin and diclofenac both increase serum potassium. Use Caution/Monitor.

  • agrimony

    diclofenac and agrimony both increase anticoagulation. Use Caution/Monitor.

  • albuterol

    diclofenac increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • alfalfa

    diclofenac and alfalfa both increase anticoagulation. Use Caution/Monitor.

  • alfuzosin

    diclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • aliskiren

    diclofenac will decrease the level or effect of aliskiren by Other (see comment). Use Caution/Monitor. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Monitor renal function periodically.

  • alpelisib

    alpelisib will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.

  • alteplase

    diclofenac and alteplase both increase anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.

  • American ginseng

    diclofenac and American ginseng both increase anticoagulation. Use Caution/Monitor.

  • amiloride

    amiloride and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.

  • antithrombin alfa

    antithrombin alfa and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • antithrombin III

    antithrombin III and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • apalutamide

    apalutamide will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Coadministration of apalutamide, a weak CYP2C9 inducer, with drugs that are CYP2C9 substrates can result in lower exposure to these medications. Evaluate for loss of therapeutic effect if medication must be coadministered.

  • arformoterol

    diclofenac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • argatroban

    argatroban and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • artesunate

    diclofenac will increase the level or effect of artesunate by decreasing metabolism. Use Caution/Monitor. Coadministration may increase active artesunate metabolite (DHA) by inhibiting UGT. Monitor for increased adverse effects.

  • asenapine

    diclofenac decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • aspirin

    aspirin and diclofenac both increase anticoagulation. Use Caution/Monitor.aspirin and diclofenac both increase serum potassium. Use Caution/Monitor.

  • aspirin rectal

    aspirin rectal and diclofenac both increase anticoagulation. Use Caution/Monitor.aspirin rectal and diclofenac both increase serum potassium. Use Caution/Monitor.

  • aspirin/citric acid/sodium bicarbonate

    aspirin/citric acid/sodium bicarbonate and diclofenac both increase anticoagulation. Use Caution/Monitor.aspirin/citric acid/sodium bicarbonate and diclofenac both increase serum potassium. Use Caution/Monitor.

  • atazanavir

    atazanavir increases levels of diclofenac by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .

  • atenolol

    atenolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of atenolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • atogepant

    diclofenac will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • avapritinib

    diclofenac will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • axitinib

    diclofenac increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • azficel-T

    azficel-T, diclofenac. Other (see comment). Use Caution/Monitor. Comment: Patients taking NSAIDS may experience increased bruising or bleeding at biopsy and/or injection sites. Concomitant use of NSAIDs is not recommended.

  • azilsartan

    diclofenac, azilsartan.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.diclofenac decreases effects of azilsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.azilsartan decreases effects of diclofenac by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.

  • bemiparin

    bemiparin and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • benazepril

    benazepril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • bendroflumethiazide

    diclofenac increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • betaxolol

    betaxolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of betaxolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • betrixaban

    diclofenac, betrixaban.Either increases levels of the other by anticoagulation. Use Caution/Monitor.

  • bimatoprost

    bimatoprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).

  • bisoprolol

    bisoprolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of bisoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • bivalirudin

    bivalirudin and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • budesonide

    diclofenac, budesonide.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • bumetanide

    diclofenac increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.diclofenac decreases effects of bumetanide by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • candesartan

    candesartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of candesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.candesartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • cannabidiol

    cannabidiol will increase the level or effect of diclofenac by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates.

  • capecitabine

    capecitabine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • captopril

    captopril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • carbenoxolone

    diclofenac increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • carvedilol

    carvedilol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • celecoxib

    celecoxib and diclofenac both increase anticoagulation. Use Caution/Monitor.celecoxib and diclofenac both increase serum potassium. Use Caution/Monitor.

  • celiprolol

    celiprolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of celiprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • chlorothiazide

    diclofenac increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • chlorpropamide

    diclofenac increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • chlorthalidone

    diclofenac increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • cholestyramine

    cholestyramine decreases levels of diclofenac by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

  • choline magnesium trisalicylate

    diclofenac and choline magnesium trisalicylate both increase anticoagulation. Use Caution/Monitor.diclofenac and choline magnesium trisalicylate both increase serum potassium. Use Caution/Monitor.

  • cinnamon

    diclofenac and cinnamon both increase anticoagulation. Use Caution/Monitor.

  • ciprofloxacin

    diclofenac, ciprofloxacin. Other (see comment). Modify Therapy/Monitor Closely. Comment: Mechanism: unknown. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.

  • citalopram

    citalopram, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.

  • clomipramine

    clomipramine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

  • clopidogrel

    clopidogrel, diclofenac.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Clopidogrel and NSAIDs both inhibit platelet aggregation.

  • cordyceps

    diclofenac and cordyceps both increase anticoagulation. Use Caution/Monitor.

  • cortisone

    diclofenac, cortisone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • cyclopenthiazide

    diclofenac increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • cyclosporine

    diclofenac, cyclosporine.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely.

  • dabigatran

    dabigatran and diclofenac both increase anticoagulation. Use Caution/Monitor. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding.

  • dalteparin

    dalteparin and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • deferasirox

    deferasirox, diclofenac. Other (see comment). Use Caution/Monitor. Comment: Combination may increase GI bleeding, ulceration and irritation. Use with caution.

  • deferiprone

    diclofenac will increase the level or effect of deferiprone by decreasing metabolism. Use Caution/Monitor. Coadministration with UGT1A6 inhibitors may increase serum concentration of deferiprone.

  • defibrotide

    defibrotide increases effects of diclofenac by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors.

  • deflazacort

    diclofenac, deflazacort.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • dexamethasone

    diclofenac, dexamethasone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • diflunisal

    diclofenac and diflunisal both increase anticoagulation. Use Caution/Monitor.diclofenac and diflunisal both increase serum potassium. Use Caution/Monitor.

  • digoxin

    diclofenac and digoxin both increase serum potassium. Use Caution/Monitor.

  • dobutamine

    diclofenac increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • dong quai

    diclofenac and dong quai both increase anticoagulation. Use Caution/Monitor.

  • dopexamine

    diclofenac increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • doxazosin

    diclofenac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

    (Video) Diclofenac | Voltaren/Cataflam | Mechanism of Action |Dosage| Indications | Adverse Effect (English)

  • drospirenone

    drospirenone and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.

  • duloxetine

    duloxetine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • edoxaban

    edoxaban, diclofenac.Either increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss.

  • efavirenz

    efavirenz will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

  • eltrombopag

    eltrombopag increases levels of diclofenac by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear.

  • elvitegravir/cobicistat/emtricitabine/tenofovir DF

    elvitegravir/cobicistat/emtricitabine/tenofovir DF decreases levels of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.elvitegravir/cobicistat/emtricitabine/tenofovir DF, diclofenac.Either increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.

  • emtricitabine

    emtricitabine, diclofenac.Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.

  • enalapril

    enalapril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • enoxaparin

    enoxaparin and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • ephedrine

    diclofenac increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • epinephrine

    diclofenac increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • epinephrine racemic

    diclofenac increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • epoprostenol

    diclofenac and epoprostenol both increase anticoagulation. Use Caution/Monitor.

  • eprosartan

    eprosartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of eprosartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.eprosartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • escitalopram

    escitalopram, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • esmolol

    esmolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of esmolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • ethacrynic acid

    diclofenac increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • etodolac

    diclofenac and etodolac both increase anticoagulation. Use Caution/Monitor.diclofenac and etodolac both increase serum potassium. Use Caution/Monitor.

  • fenbufen

    diclofenac and fenbufen both increase anticoagulation. Use Caution/Monitor.diclofenac and fenbufen both increase serum potassium. Use Caution/Monitor.

  • fennel

    diclofenac and fennel both increase anticoagulation. Use Caution/Monitor.

  • fenoprofen

    diclofenac and fenoprofen both increase anticoagulation. Use Caution/Monitor.diclofenac and fenoprofen both increase serum potassium. Use Caution/Monitor.

  • feverfew

    diclofenac and feverfew both increase anticoagulation. Use Caution/Monitor.

  • finerenone

    diclofenac will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.

  • fish oil triglycerides

    fish oil triglycerides will increase the level or effect of diclofenac by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants.

  • flibanserin

    diclofenac will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.

  • fluconazole

    fluconazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • fludrocortisone

    diclofenac, fludrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • fluorouracil

    fluorouracil will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • fluoxetine

    fluoxetine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.fluoxetine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • flurbiprofen

    diclofenac and flurbiprofen both increase anticoagulation. Use Caution/Monitor.diclofenac and flurbiprofen both increase serum potassium. Use Caution/Monitor.

  • fluvoxamine

    fluvoxamine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • fondaparinux

    fondaparinux and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • formoterol

    diclofenac increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • forskolin

    diclofenac and forskolin both increase anticoagulation. Use Caution/Monitor.

  • fosinopril

    fosinopril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • furosemide

    diclofenac increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • garlic

    diclofenac and garlic both increase anticoagulation. Use Caution/Monitor.

  • gemfibrozil

    gemfibrozil will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • gemifloxacin

    gemifloxacin, diclofenac. Other (see comment). Modify Therapy/Monitor Closely. Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.

  • gentamicin

    diclofenac increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • ginger

    diclofenac and ginger both increase anticoagulation. Use Caution/Monitor.

  • ginkgo biloba

    diclofenac and ginkgo biloba both increase anticoagulation. Use Caution/Monitor.

  • glimepiride

    diclofenac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • glipizide

    diclofenac increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • glyburide

    diclofenac increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • green tea

    green tea, diclofenac. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.

  • heparin

    heparin and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • horse chestnut seed

    diclofenac and horse chestnut seed both increase anticoagulation. Use Caution/Monitor.

  • hydralazine

    diclofenac decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • hydrochlorothiazide

    diclofenac increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • hydrocortisone

    diclofenac, hydrocortisone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • ibrutinib

    ibrutinib will increase the level or effect of diclofenac by anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding.

  • ibuprofen

    diclofenac and ibuprofen both increase anticoagulation. Use Caution/Monitor.diclofenac and ibuprofen both increase serum potassium. Use Caution/Monitor.

  • ibuprofen IV

    diclofenac will increase the level or effect of ibuprofen IV by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.diclofenac and ibuprofen IV both increase anticoagulation. Use Caution/Monitor.diclofenac and ibuprofen IV both increase serum potassium. Use Caution/Monitor.

  • imatinib

    imatinib will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.imatinib, diclofenac.Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents.

  • indapamide

    diclofenac increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • indomethacin

    diclofenac and indomethacin both increase anticoagulation. Use Caution/Monitor.diclofenac and indomethacin both increase serum potassium. Use Caution/Monitor.

  • irbesartan

    irbesartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of irbesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.irbesartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • isavuconazonium sulfate

    diclofenac will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • isoproterenol

    diclofenac increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • ivacaftor

    diclofenac increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .

  • ketoconazole

    ketoconazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • ketoprofen

    diclofenac and ketoprofen both increase anticoagulation. Use Caution/Monitor.diclofenac and ketoprofen both increase serum potassium. Use Caution/Monitor.

  • ketorolac

    diclofenac and ketorolac both increase anticoagulation. Use Caution/Monitor.diclofenac and ketorolac both increase serum potassium. Use Caution/Monitor.

  • ketorolac intranasal

    diclofenac and ketorolac intranasal both increase anticoagulation. Use Caution/Monitor.diclofenac and ketorolac intranasal both increase serum potassium. Use Caution/Monitor.

  • labetalol

    labetalol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • latanoprost

    latanoprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).

  • latanoprostene bunod ophthalmic

    latanoprostene bunod ophthalmic, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).

  • lemborexant

    diclofenac will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.

  • levalbuterol

    diclofenac increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • levofloxacin

    levofloxacin, diclofenac. Other (see comment). Modify Therapy/Monitor Closely. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.

  • levoketoconazole

    levoketoconazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • levomilnacipran

    levomilnacipran, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.

  • lisinopril

    lisinopril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

    (Video) Which Drugs Potentiate Effect Of Warfarin? Learn Drugs With Tricks-Easy Way To Learn Drugs by MSQ

  • lithium

    diclofenac increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.

  • lomitapide

    diclofenac increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.

  • lornoxicam

    diclofenac and lornoxicam both increase anticoagulation. Use Caution/Monitor.diclofenac and lornoxicam both increase serum potassium. Use Caution/Monitor.

  • losartan

    losartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.losartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • lumacaftor/ivacaftor

    lumacaftor/ivacaftor, diclofenac. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .

  • meclofenamate

    diclofenac and meclofenamate both increase anticoagulation. Use Caution/Monitor.diclofenac and meclofenamate both increase serum potassium. Use Caution/Monitor.

  • mefenamic acid

    diclofenac and mefenamic acid both increase anticoagulation. Use Caution/Monitor.diclofenac and mefenamic acid both increase serum potassium. Use Caution/Monitor.

  • melatonin

    melatonin increases effects of diclofenac by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.

  • meloxicam

    diclofenac and meloxicam both increase anticoagulation. Use Caution/Monitor.diclofenac and meloxicam both increase serum potassium. Use Caution/Monitor.

  • mesalamine

    mesalamine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.

  • metaproterenol

    diclofenac increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • methyclothiazide

    diclofenac increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

  • methylprednisolone

    diclofenac, methylprednisolone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • metolazone

    diclofenac increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • metoprolol

    metoprolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • midazolam intranasal

    diclofenac will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.

  • milnacipran

    milnacipran, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • mipomersen

    mipomersen, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.

  • mistletoe

    diclofenac increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • moexipril

    moexipril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • moxifloxacin

    moxifloxacin, diclofenac. Other (see comment). Modify Therapy/Monitor Closely. Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.

  • moxisylyte

    diclofenac decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • mycophenolate

    diclofenac will increase the level or effect of mycophenolate by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.

  • nabumetone

    diclofenac and nabumetone both increase anticoagulation. Use Caution/Monitor.diclofenac and nabumetone both increase serum potassium. Use Caution/Monitor.

  • nadolol

    nadolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • naproxen

    diclofenac and naproxen both increase anticoagulation. Use Caution/Monitor.diclofenac and naproxen both increase serum potassium. Use Caution/Monitor.

  • nebivolol

    nebivolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • nefazodone

    nefazodone, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • nettle

    diclofenac increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • nicardipine

    nicardipine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • nitisinone

    nitisinone will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.

  • norepinephrine

    diclofenac increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • olmesartan

    olmesartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.olmesartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • oxaprozin

    diclofenac and oxaprozin both increase anticoagulation. Use Caution/Monitor.diclofenac and oxaprozin both increase serum potassium. Use Caution/Monitor.

  • panax ginseng

    diclofenac and panax ginseng both increase anticoagulation. Use Caution/Monitor.

  • parecoxib

    diclofenac and parecoxib both increase anticoagulation. Use Caution/Monitor.diclofenac and parecoxib both increase serum potassium. Use Caution/Monitor.

  • paroxetine

    paroxetine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • pau d'arco

    diclofenac and pau d'arco both increase anticoagulation. Use Caution/Monitor.

  • pegaspargase

    pegaspargase increases effects of diclofenac by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.

  • peginterferon alfa 2b

    peginterferon alfa 2b decreases levels of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .

  • penbutolol

    penbutolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of penbutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • perindopril

    perindopril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • phenindione

    phenindione and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • phenoxybenzamine

    diclofenac decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • phentolamine

    diclofenac decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • phytoestrogens

    diclofenac and phytoestrogens both increase anticoagulation. Use Caution/Monitor.

  • pindolol

    pindolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of pindolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • pirbuterol

    diclofenac increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • piroxicam

    diclofenac and piroxicam both increase anticoagulation. Use Caution/Monitor.diclofenac and piroxicam both increase serum potassium. Use Caution/Monitor.

  • pivmecillinam

    pivmecillinam, diclofenac.Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.pivmecillinam, diclofenac.Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.

  • potassium acid phosphate

    diclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

  • potassium chloride

    diclofenac and potassium chloride both increase serum potassium. Modify Therapy/Monitor Closely.

  • potassium citrate

    diclofenac and potassium citrate both increase serum potassium. Modify Therapy/Monitor Closely.

  • potassium iodide

    potassium iodide and diclofenac both increase serum potassium. Use Caution/Monitor.

  • pralatrexate

    diclofenac increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.

  • prasugrel

    diclofenac, prasugrel.Either increases effects of the other by anticoagulation. Use Caution/Monitor. Chronic use of NSAIDs with prasugrel may increase bleeding risk.

  • prazosin

    diclofenac decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • prednisolone

    diclofenac, prednisolone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • prednisone

    diclofenac, prednisone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.

  • probenecid

    diclofenac will increase the level or effect of probenecid by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.

  • propranolol

    propranolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of propranolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • protamine

    protamine and diclofenac both increase anticoagulation. Modify Therapy/Monitor Closely.

  • quinapril

    quinapril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • ramipril

    ramipril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • reishi

    diclofenac and reishi both increase anticoagulation. Use Caution/Monitor.

  • reteplase

    diclofenac and reteplase both increase anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.

  • rivaroxaban

    rivaroxaban, diclofenac. Other (see comment). Use Caution/Monitor. Comment: NSAIDs are known to increase bleeding. Bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Monitor for signs/symptoms of blood loss.

  • rivastigmine

    rivastigmine increases toxicity of diclofenac by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding.

  • rucaparib

    rucaparib will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP2C9 substrates, if clinically indicated.

  • sacubitril/valsartan

    sacubitril/valsartan and diclofenac both increase serum potassium. Use Caution/Monitor.sacubitril/valsartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.diclofenac decreases effects of sacubitril/valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.

  • salicylates (non-asa)

    diclofenac and salicylates (non-asa) both increase anticoagulation. Use Caution/Monitor.diclofenac and salicylates (non-asa) both increase serum potassium. Use Caution/Monitor.

  • salmeterol

    diclofenac increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • salsalate

    diclofenac and salsalate both increase anticoagulation. Use Caution/Monitor.diclofenac and salsalate both increase serum potassium. Use Caution/Monitor.

  • saw palmetto

    saw palmetto increases toxicity of diclofenac by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding.

    (Video) Pain Management: Medication – Dr. Feelgood or Bad Medicine - CareOregon MEDS Ed Seminar (2/5)

  • sertraline

    sertraline, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • Siberian ginseng

    diclofenac and Siberian ginseng both increase anticoagulation. Use Caution/Monitor.

  • silodosin

    diclofenac decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • sodium picosulfate/magnesium oxide/anhydrous citric acid

    diclofenac, sodium picosulfate/magnesium oxide/anhydrous citric acid.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May be associated with fluid and electrolyte imbalances.

  • sodium sulfate/?magnesium sulfate/potassium chloride

    sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of diclofenac by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

  • sodium sulfate/potassium sulfate/magnesium sulfate

    sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of diclofenac by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

  • sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol

    diclofenac, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.

  • sotalol

    sotalol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • spironolactone

    spironolactone and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.

  • succinylcholine

    diclofenac and succinylcholine both increase serum potassium. Use Caution/Monitor.

  • sulfadiazine

    sulfadiazine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • sulfasalazine

    diclofenac and sulfasalazine both increase anticoagulation. Use Caution/Monitor.diclofenac and sulfasalazine both increase serum potassium. Use Caution/Monitor.

  • sulindac

    diclofenac and sulindac both increase anticoagulation. Use Caution/Monitor.diclofenac and sulindac both increase serum potassium. Use Caution/Monitor.

  • tafluprost

    tafluprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).

  • tazemetostat

    diclofenac will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • telmisartan

    telmisartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of telmisartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.telmisartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • temocillin

    temocillin, diclofenac.Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.temocillin, diclofenac.Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.

  • tenecteplase

    diclofenac and tenecteplase both increase anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.

  • tenofovir DF

    tenofovir DF, diclofenac.Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of tenofovir DF with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.

  • terazosin

    diclofenac decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • terbutaline

    diclofenac increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • teriflunomide

    teriflunomide increases levels of diclofenac by Other (see comment). Use Caution/Monitor. Comment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates.

  • ticagrelor

    ticagrelor, diclofenac.Either increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding with use of ticagrelor and chronic NSAID use. .

  • ticarcillin

    ticarcillin, diclofenac.Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.ticarcillin, diclofenac.Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.

  • timolol

    timolol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

  • tinidazole

    diclofenac will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • tolazamide

    diclofenac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • tolbutamide

    diclofenac increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.tolbutamide will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • tolfenamic acid

    diclofenac and tolfenamic acid both increase anticoagulation. Use Caution/Monitor.diclofenac and tolfenamic acid both increase serum potassium. Use Caution/Monitor.

  • tolmetin

    diclofenac and tolmetin both increase anticoagulation. Use Caution/Monitor.diclofenac and tolmetin both increase serum potassium. Use Caution/Monitor.

  • tolvaptan

    diclofenac and tolvaptan both increase serum potassium. Use Caution/Monitor.

  • torsemide

    diclofenac increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

  • trandolapril

    trandolapril, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • travoprost ophthalmic

    travoprost ophthalmic, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).

  • trazodone

    trazodone, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • triamcinolone acetonide injectable suspension

    diclofenac, triamcinolone acetonide injectable suspension.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Concomitant use of NSAIDS and corticosteroids increases the risk of gastrointestinal side effects. .

  • triamterene

    triamterene and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.

  • valsartan

    valsartan and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.valsartan, diclofenac.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.

  • venlafaxine

    venlafaxine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.

  • voclosporin

    voclosporin, diclofenac.Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

  • vorapaxar

    diclofenac, vorapaxar.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur.

  • voriconazole

    voriconazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

  • vortioxetine

    diclofenac, vortioxetine.Either increases effects of the other by anticoagulation. Use Caution/Monitor.

  • warfarin

    diclofenac, warfarin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Drugs with antiplatelet properties may increase anticoagulation effect of warfarin.

  • zanubrutinib

    diclofenac, zanubrutinib.Either increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk.

  • zotepine

    diclofenac decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

  • aceclofenac

    aceclofenac will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • acemetacin

    acemetacin will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • acyclovir

    diclofenac will increase the level or effect of acyclovir by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • alendronate

    diclofenac, alendronate.Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.

  • amikacin

    diclofenac increases levels of amikacin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • aminohippurate sodium

    diclofenac will increase the level or effect of aminohippurate sodium by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • amiodarone

    amiodarone will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • amobarbital

    amobarbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • anamu

    diclofenac and anamu both increase anticoagulation. Minor/Significance Unknown.

  • aspirin

    aspirin will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • aspirin rectal

    aspirin rectal will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • aspirin/citric acid/sodium bicarbonate

    aspirin/citric acid/sodium bicarbonate will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • balsalazide

    diclofenac will increase the level or effect of balsalazide by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • bendroflumethiazide

    bendroflumethiazide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • bosentan

    bosentan will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • butabarbital

    butabarbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • butalbital

    butalbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • carbamazepine

    carbamazepine will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • cefadroxil

    cefadroxil will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • cefamandole

    cefamandole will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • cefpirome

    cefpirome will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • celecoxib

    celecoxib will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • cephalexin

    cephalexin will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • chlorothiazide

    chlorothiazide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • chlorpropamide

    diclofenac will increase the level or effect of chlorpropamide by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • chlorthalidone

    chlorthalidone will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • choline magnesium trisalicylate

    diclofenac will increase the level or effect of choline magnesium trisalicylate by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

    (Video) Implementing Pharmacogenetics with Kristen Reynolds

  • cimetidine

    cimetidine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • colestipol

    colestipol decreases levels of diclofenac by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

  • creatine

    creatine, diclofenac. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects.

  • cyclopenthiazide

    cyclopenthiazide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • danshen

    diclofenac and danshen both increase anticoagulation. Minor/Significance Unknown.

  • devil's claw

    diclofenac and devil's claw both increase anticoagulation. Minor/Significance Unknown.

  • diclofenac topical

    diclofenac topical, diclofenac.Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Although low, there is systemic exposure to diclofenac topical; theoretically, concomitant administration with systemic NSAIDS or aspirin may result in increased NSAID adverse effects.

  • diflunisal

    diclofenac will increase the level or effect of diflunisal by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • disulfiram

    disulfiram will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • eplerenone

    diclofenac decreases effects of eplerenone by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.

  • etodolac

    diclofenac will increase the level or effect of etodolac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • etravirine

    etravirine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • felbamate

    felbamate will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • fenbufen

    diclofenac will increase the level or effect of fenbufen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • fenoprofen

    diclofenac will increase the level or effect of fenoprofen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • feverfew

    diclofenac decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown.

  • flurbiprofen

    diclofenac will increase the level or effect of flurbiprofen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • furosemide

    diclofenac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.

  • ganciclovir

    diclofenac will increase the level or effect of ganciclovir by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • gentamicin

    diclofenac increases levels of gentamicin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • hydrochlorothiazide

    hydrochlorothiazide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ibuprofen

    diclofenac will increase the level or effect of ibuprofen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • imidapril

    diclofenac decreases effects of imidapril by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.

  • indapamide

    indapamide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • indomethacin

    diclofenac will increase the level or effect of indomethacin by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ketoprofen

    diclofenac will increase the level or effect of ketoprofen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ketorolac

    diclofenac will increase the level or effect of ketorolac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ketorolac intranasal

    diclofenac will increase the level or effect of ketorolac intranasal by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • leflunomide

    leflunomide will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • lornoxicam

    diclofenac will increase the level or effect of lornoxicam by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • meclofenamate

    diclofenac will increase the level or effect of meclofenamate by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • mefenamic acid

    diclofenac will increase the level or effect of mefenamic acid by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • meloxicam

    diclofenac will increase the level or effect of meloxicam by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • mesalamine

    diclofenac will increase the level or effect of mesalamine by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • methyclothiazide

    methyclothiazide will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • metolazone

    metolazone will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • metronidazole

    metronidazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • miconazole vaginal

    miconazole vaginal will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • nabumetone

    diclofenac will increase the level or effect of nabumetone by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • naproxen

    diclofenac will increase the level or effect of naproxen by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • nateglinide

    nateglinide will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • neomycin PO

    diclofenac increases levels of neomycin PO by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • nilotinib

    nilotinib will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • noni juice

    diclofenac and noni juice both increase serum potassium. Minor/Significance Unknown.

  • ofloxacin

    ofloxacin, diclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.

  • oxaprozin

    diclofenac will increase the level or effect of oxaprozin by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • parecoxib

    diclofenac will increase the level or effect of parecoxib by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • paromomycin

    diclofenac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • pentobarbital

    pentobarbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • phenobarbital

    phenobarbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • piroxicam

    diclofenac will increase the level or effect of piroxicam by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • primidone

    primidone will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • rifampin

    rifampin will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • rifapentine

    rifapentine will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • rose hips

    rose hips will increase the level or effect of diclofenac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ruxolitinib

    diclofenac will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

  • ruxolitinib topical

    diclofenac will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

  • salicylates (non-asa)

    diclofenac will increase the level or effect of salicylates (non-asa) by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • salsalate

    diclofenac will increase the level or effect of salsalate by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • secobarbital

    secobarbital will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • streptomycin

    diclofenac increases levels of streptomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • sulfamethoxazole

    sulfamethoxazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • sulfasalazine

    diclofenac will increase the level or effect of sulfasalazine by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • sulindac

    diclofenac will increase the level or effect of sulindac by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • ticlopidine

    ticlopidine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • tobramycin

    diclofenac increases levels of tobramycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

  • tolfenamic acid

    diclofenac will increase the level or effect of tolfenamic acid by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • tolmetin

    diclofenac will increase the level or effect of tolmetin by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • triamterene

    triamterene, diclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.diclofenac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.

  • valganciclovir

    diclofenac will increase the level or effect of valganciclovir by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • valproic acid

    valproic acid will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

  • vancomycin

    diclofenac increases levels of vancomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in neonates.

  • willow bark

    diclofenac will increase the level or effect of willow bark by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.

  • zafirlukast

    zafirlukast will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.

    (Video) Top 200 Prescription Drugs:( 1 - 200 ) WITH AUDIO | PTCB |(Pharmacy Technician Exam) |Exam Top Video

  • FAQs

    What are the indications of diclofenac? ›

    Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma.

    What is the dosing for Voltaren? ›

    For osteoarthritis of the hands, elbows, or wrists using Voltaren® 1% gel: Adults—Apply 2 grams (g) to the affected skin areas four times a day (a total of 8 g each day). However, the total dose should not exceed 32 g per day over all affected joints.

    What does Voltaren interact with? ›

    Voltaren may interact with antidepressants, blood thinners, cyclosporine, isoniazid, lithium, methotrexate, pronbenecid, rifampin, secobarbital, sertraline, sulfamethoxazole, teniposide, zafirlukast, diuretics (water pills), steroids, antifungal medications, aspirin or other NSAIDs (nonsteroidal anti-inflammatory drugs ...

    Which is better Voltaren or Cataflam? ›

    Cataflam has an average rating of 8.4 out of 10 from a total of 48 ratings on Drugs.com. 85% of reviewers reported a positive effect, while 9% reported a negative effect. Voltaren has an average rating of 7.4 out of 10 from a total of 161 ratings on Drugs.com.

    What is the side effects of diclofenac? ›

    Common side effects
    • feeling sick (nausea)
    • being sick (vomiting) or diarrhoea.
    • feeling dizzy or vertigo.
    • headaches.
    • stomach ache, wind or loss of appetite.
    • mild rash.

    Does Voltaren raise blood pressure? ›

    Many people using this medication do not have serious side effects. This medication may raise your blood pressure.

    Does diclofenac raise blood pressure? ›

    Diclofenac does not increase the risk of hypertension, but does increase the risk of stroke. Naproxen (Naprosyn) does not increase the risk of hypertension or stroke.

    What is Cataflam used for? ›

    Cataflam is used to treat a number of painful conditions including: • joint, muscle or tendon pain • attacks of gout • pain and swelling caused after surgery • sprains, strains and other injuries • gynaecology problems such as period pain • painful ear, nose or throat infections • migraine.

    Is diclofenac harmful to kidneys? ›

    Diclofenac and other non-steroidal anti-inflammatory drugs (NSAID's) cause the kidney to lose the capacity to make these protective hormones and over time, can result in progressive kidney damage. This damage may take years in some people but in others can occur after a single dose.

    Who shouldnt take diclofenac? ›

    In line with COX-2 inhibitors, diclofenac is now contraindicated in people with ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, and established congestive heart failure (New York Heart Association classification II-IV).

    What medications should not be taken with Voltaren? ›

    Some products that may interact with this drug include: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as valsartan, losartan), corticosteroids (such as prednisone), cidofovir, lithium, methotrexate, "water pills" (diuretics such as furosemide).

    What drugs should not be taken with diclofenac? ›

    Some products that may interact with this drug include: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as valsartan, losartan), corticosteroids (such as prednisone), cidofovir, lithium, methotrexate, "water pills" (diuretics such as furosemide).

    What are the contraindication of diclofenac? ›

    diclofenac is now contraindicated in patients with established: ischaemic heart disease. peripheral arterial disease. cerebrovascular disease.

    What kind of pain does diclofenac relieve? ›

    Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild-to-moderate pain, and helps to relieve symptoms of arthritis (eg, osteoarthritis or rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.

    What is the indication of ibuprofen? ›

    IBUPROFEN INDICATIONS

    Like other OTC pain relievers, ibuprofen temporarily relieves minor aches and pains due to headache, backache, the common cold, minor pain of arthritis, toothache, menstrual cramps, and muscular aches, and temporarily reduces fever.

    Is diclofenac a strong painkiller? ›

    Diclofenac is considered more potent than ibuprofen and needs to be taken two or three times per day. Ibuprofen often needs to be taken in higher doses to treat pain from arthritis.

    1. "Медицина в условиях пандемии: грипп, COVID-19 и проблемы обезболивания." Вебинар 29.01.2021
    (ASFARMA Russia)

    You might also like

    Latest Posts

    Article information

    Author: Lakeisha Bayer VM

    Last Updated: 09/14/2022

    Views: 6238

    Rating: 4.9 / 5 (69 voted)

    Reviews: 92% of readers found this page helpful

    Author information

    Name: Lakeisha Bayer VM

    Birthday: 1997-10-17

    Address: Suite 835 34136 Adrian Mountains, Floydton, UT 81036

    Phone: +3571527672278

    Job: Manufacturing Agent

    Hobby: Skimboarding, Photography, Roller skating, Knife making, Paintball, Embroidery, Gunsmithing

    Introduction: My name is Lakeisha Bayer VM, I am a brainy, kind, enchanting, healthy, lovely, clean, witty person who loves writing and wants to share my knowledge and understanding with you.